Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Eli Lilly's bet on the Oscars shows the GLP-1 ad wars are heating up. - Eli Lilly. At the 2024 Academy Awards, Eli Lilly, the ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Discover Eli Lilly's latest offering of discounted high-dose Zepbound vials, now available for $499 for a four-week supply.

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...